These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22724421)

  • 21. Development and clinical use of prasugrel and ticagrelor.
    Ahmad S; Storey RF
    Curr Pharm Des; 2012; 18(33):5240-60. PubMed ID: 22724412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiplatelet agents in acute coronary syndromes.
    Sakhuja R; Yeh RW; Bhatt DL
    Curr Probl Cardiol; 2010 Mar; 35(3):123-70. PubMed ID: 20152547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease.
    Nathan AS; Sen S; Yeh RW
    Expert Opin Drug Saf; 2017 May; 16(5):561-572. PubMed ID: 28387542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Another view on prasugrel.
    Calatzis A
    Thromb Haemost; 2009 Jan; 101(1):12-3. PubMed ID: 19132183
    [No Abstract]   [Full Text] [Related]  

  • 25. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New input on antiplatelet treatment and registry studies.
    Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2018 Jul; 4(3):129-130. PubMed ID: 30052852
    [No Abstract]   [Full Text] [Related]  

  • 27. Response variability to P2Y12 receptor inhibitors: expectations and reality.
    Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is heparin an acceptable anticoagulant when glycoprotein IIb/IIIa inhibitors are not used?
    Lee MS; Rha SW; Park KW; Kim MH
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):223-224. PubMed ID: 25616929
    [No Abstract]   [Full Text] [Related]  

  • 29. Post-thienopyridine platelet response, cardiovascular outcomes, and personalized therapy: En attendant Godot.
    Tsimikas S; Leibundgut G
    JACC Cardiovasc Interv; 2010 Jun; 3(6):657-9. PubMed ID: 20630459
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacogenetics of the antiplatelet effect of aspirin.
    Würtz M; Kristensen SD; Hvas AM; Grove EL
    Curr Pharm Des; 2012; 18(33):5294-308. PubMed ID: 22724416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of antiplatelet therapy on platelet extracellular vesicle release and procoagulant activity in health and in cardiovascular disease.
    Connor DE; Ly K; Aslam A; Boland J; Low J; Jarvis S; Muller DW; Joseph JE
    Platelets; 2016 Dec; 27(8):805-811. PubMed ID: 27310292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of perioperative antiplatelet therapy and platelet reactivity testing in carotid revascularization: overview of the evidence.
    Leunissen TC; De Borst GJ; Janssen PW; ten Berg JM
    J Cardiovasc Surg (Torino); 2015 Apr; 56(2):165-75. PubMed ID: 25600432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance.
    Siller-Matula J; Schrör K; Wojta J; Huber K
    Thromb Haemost; 2007 Mar; 97(3):385-93. PubMed ID: 17334505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
    Laine M; Camoin-Jau L; Bessereau J; Sébastien A; Paganelli F; Bonello L
    Curr Pharm Des; 2012; 18(33):5392-401. PubMed ID: 22724420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting glycoprotein VI and the immunoreceptor tyrosine-based activation motif signaling pathway.
    Stegner D; Haining EJ; Nieswandt B
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1615-20. PubMed ID: 24925975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolong antiplatelet therapy. Where we stand?
    Tousoulis D
    Hellenic J Cardiol; 2019; 60(5):269-270. PubMed ID: 32014559
    [No Abstract]   [Full Text] [Related]  

  • 37. Pretreatment with P2Y12 inhibitors in non-ST-segment elevation acute coronary syndrome: Time to revise the guidelines?
    Cayla G; Collet JP; Silvain J; Montalescot G
    Arch Cardiovasc Dis; 2014 Jan; 107(1):1-3. PubMed ID: 24332911
    [No Abstract]   [Full Text] [Related]  

  • 38. The effects of ginsenosides on platelet aggregation and vascular intima in the treatment of cardiovascular diseases: From molecular mechanisms to clinical applications.
    Luo BY; Jiang JL; Fang YF; Yang F; Yin MD; Zhang BC; Zhao RR; Shao JW
    Pharmacol Res; 2020 Sep; 159():105031. PubMed ID: 32562816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic and acquired determinants of individual variability of response to antiplatelet drugs.
    Schafer AI
    Circulation; 2003 Aug; 108(8):910-1. PubMed ID: 12939239
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics.
    Hernandez-Suarez DF; Scott SA; Tomey MI; Melin K; Lopez-Candales A; Buckley CE; Duconge J
    Ther Adv Cardiovasc Dis; 2017 Sep; 11(9):235-241. PubMed ID: 28675986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.